NASDAQ:ADMA - ADMA Biologics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$3.22 -0.18 (-5.29 %)
(As of 01/23/2019 04:00 PM ET)
Previous Close$3.40
Today's Range$3.16 - $3.45
52-Week Range$2.08 - $6.96
Volume278,833 shs
Average Volume317,429 shs
Market Capitalization$149.25 million
P/E Ratio-1.69
Dividend YieldN/A
Beta2.84
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease. The company also operates source plasma collection facilities in Norcross and Marietta, Georgia. In Addition, the company offers Nabi-HB for the treatment of acute exposure; and Bivigam for the treatment of primary humoral immunodeficiency. It distributes its products through independent distributors, sales agents, specialty pharmacies, and others. The ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.

Receive ADMA News and Ratings via Email

Sign-up to receive the latest news and ratings for ADMA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ADMA
CUSIPN/A
Phone201-478-5552

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$22.76 million
Book Value$0.89 per share

Profitability

Net Income$-43,750,000.00
Net Margins-243.42%

Miscellaneous

Employees295
Market Cap$149.25 million
OptionableOptionable

ADMA Biologics (NASDAQ:ADMA) Frequently Asked Questions

What is ADMA Biologics' stock symbol?

ADMA Biologics trades on the NASDAQ under the ticker symbol "ADMA."

How were ADMA Biologics' earnings last quarter?

ADMA Biologics Inc (NASDAQ:ADMA) posted its quarterly earnings results on Thursday, November, 8th. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.31) by $0.02. The biotechnology company earned $4.23 million during the quarter, compared to the consensus estimate of $5.39 million. ADMA Biologics had a negative return on equity of 155.19% and a negative net margin of 243.42%. View ADMA Biologics' Earnings History.

When is ADMA Biologics' next earnings date?

ADMA Biologics is scheduled to release their next quarterly earnings announcement on Monday, March 4th 2019. View Earnings Estimates for ADMA Biologics.

What price target have analysts set for ADMA?

4 Wall Street analysts have issued 1-year target prices for ADMA Biologics' stock. Their forecasts range from $7.50 to $17.00. On average, they expect ADMA Biologics' share price to reach $11.5833 in the next year. This suggests a possible upside of 259.7% from the stock's current price. View Analyst Price Targets for ADMA Biologics.

What is the consensus analysts' recommendation for ADMA Biologics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ADMA Biologics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ADMA Biologics.

What are Wall Street analysts saying about ADMA Biologics stock?

Here are some recent quotes from research analysts about ADMA Biologics stock:
  • 1. HC Wainwright analysts commented, "Our price target of $3/share is based on a discounted cash flow analysis (2018-2026) using a 12% discount rate and 2% growth rate, in line with the expected discount and growth parameters of a development-stage drug company. Risks to our investment thesis and target price include: (1) failure in clinical studies; (2) failure to secure regulatory approval; and (3) smaller than anticipated commercial opportunity due to market size, competition and pricing. Bellerophon Therapeutics, Inc." (11/9/2018)
  • 2. Maxim Group analysts commented, "ADMA announced that FDA has accepted the BLA resubmission for RI-002, the company’s specialized IVIG immunoglobulin for Primary Immune Deficiency Disease (PIDD) and assigned a PDUFA date on April 2, 2019." (10/17/2018)

Has ADMA Biologics been receiving favorable news coverage?

Press coverage about ADMA stock has trended somewhat positive on Wednesday, according to InfoTrie Sentiment. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. ADMA Biologics earned a coverage optimism score of 1.0 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 3.0 out of 10, meaning that recent news coverage is unlikely to have an impact on the stock's share price in the near term.

Who are some of ADMA Biologics' key competitors?

Who are ADMA Biologics' key executives?

ADMA Biologics' management team includes the folowing people:
  • Mr. Adam S. Grossman, Co-Founder, Pres, CEO & Director (Age 42)
  • Dr. Jerrold B. Grossman D.P.S., Co-Founder & Vice Chairman (Age 71)
  • Mr. Brian Lenz CPA, Exec. VP & CFO (Age 47)
  • Dr. James Mond, Exec. VP, Chief Scientific Officer & Chief Medical Officer (Age 73)
  • Mr. James Hauert, Sr. VP of Commercialization & Strategy

How do I buy shares of ADMA Biologics?

Shares of ADMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ADMA Biologics' stock price today?

One share of ADMA stock can currently be purchased for approximately $3.22.

How big of a company is ADMA Biologics?

ADMA Biologics has a market capitalization of $149.25 million and generates $22.76 million in revenue each year. The biotechnology company earns $-43,750,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis. ADMA Biologics employs 295 workers across the globe.

What is ADMA Biologics' official website?

The official website for ADMA Biologics is http://www.admabiologics.com.

How can I contact ADMA Biologics?

ADMA Biologics' mailing address is 465 STATE ROUTE 17, RAMSEY NJ, 07446. The biotechnology company can be reached via phone at 201-478-5552 or via email at [email protected]


MarketBeat Community Rating for ADMA Biologics (NASDAQ ADMA)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  251 (Vote Outperform)
Underperform Votes:  149 (Vote Underperform)
Total Votes:  400
MarketBeat's community ratings are surveys of what our community members think about ADMA Biologics and other stocks. Vote "Outperform" if you believe ADMA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADMA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel